Valuing health-related quality of life: systematic variation in health perception by Huber, Manuel et al.
RESEARCH Open Access
Valuing health-related quality of life:
systematic variation in health perception
Manuel Huber1* , Martin Vogelmann2 and Reiner Leidl1,3
Abstract
Background: Population-based value sets are widely used to transform health states into utilities, but may deviate
from actual patient experience. Whether this occurs in a systematic way can be analyzed, in a first step, for
respondents who do not report problems on the five domains of the EQ-5D-5L instrument in population studies.
Methods: EQ-5D-5L results from three annual cross-sectional surveys (2012, 2013, and 2014) were filtered for
participants who reported being problem-free. Continuous visual analog scale (VAS) scores, ranging from 0
(worst imaginable health) to 100 (best imaginable health) were then used to measure their actual health perception
and to compare results with the proposed EQ-5D-5L value. A multiple linear regression model was used to identify
possible risk factors for low VAS scores.
Results: Some 3739 (61.5%) participants reported being problem-free. Their mean age was 41.1 years and mean VAS
score was 91.9. Age and BMI were significantly associated with lower VAS scores. Age groups from 50 years onwards
reported VAS means of 90.0 and below. Female gender and low education also had small but significant negative
effects on patient experience. The presence of BMI class III as well as diabetes had the greatest negative effect on VAS
results (− 9.0 and − 8.4) and reached the range of minimally important differences. Heart disease (− 6.2) and
musculoskeletal disease (− 3.4) also had strong negative effects. The 25th percentile of VAS scores in our sample was
90.0, and the 50th percentile was 95.0.
Conclusions: For some groups in population studies, especially older people with high BMI and those affected by
specific diseases, no problems on all five domains of the EQ-5D-5L fails to reflect the respondents’ health perception as
measured by the VAS.
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Background
In addition to mortality and clinical outcomes, health-re-
lated quality of life (HRQoL) can be used to evaluate
and compare the effectiveness of healthcare interven-
tions. HRQoL is measured by different instruments in-
cluding the widely used EQ-5D [1–6]. The EQ-5D is a
generic instrument consisting of five questions, referred
to as dimensions. They are directed at different aspects
of health (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression). For each dimension,
either three (3L version) or five (5L version) predefined
answers exist. Answer possibilities range from no
problem (=1) to extreme problems (=3 or 5, depending
on the version) and make up the so called EQ-5D health
state, a HRQoL profile (for reasons of compliance and
standardization the term health state always refers to
EQ-5D health state in this study). The visual analog
scale (VAS) is also part of the EQ-5D-5L and is a con-
tinuous scale ranging from 0 (the worst health the re-
sponder can imagine) to 100 (the best health the
responder can imagine). The VAS lets participants rate
their overall health. Both the descriptive system and the
VAS ask for health perception on the day of the survey.
Self-reported EQ-5D data are often transformed into
utilities to calculate quality-adjusted life years (QALYs)
for cost-effectiveness analyses. The utilities are located
on a scale anchored at 0 (dead) and ending at 1 (report-
ing no problems). The transformation into utilities is
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mostly achieved by applying country-specific value sets
that assign fixed utilities for each health state [7]. These
value sets are mostly created by asking representative
samples of the population to value a number of
hypothetical health states. Evidence suggests that
population-based value sets may suffer from unin-
formed preferences of the general public [8]. Ratings
are mainly done by applying the time-trade-off (TTO)
method, which asks participants to trade time (e.g.,
years somebody is willing to die earlier) for perfect
health. The most widely used value set for Germany
and the EQ-5D-3L assigns a value of 1.00 to all respon-
dents who report no problems (= 11111) in any of the
five dimensions of the EQ-5D [9]. There are also value
sets that are based on the health state currently experi-
enced by the respondent. Respective value sets have
been derived for the German population based on VAS
valuations and the EQ-5D-3L [10] as well as on the
EQ-5D-5L [11]. For the problem-free health state, these
studies estimated a VAS value of 89.34 and 91.96 re-
spectively. This lower valuation may reflect average
health perception and may be used to calculate
quality-adjusted survival, although it does not fulfill the
requirements of the QALY concept [11]. Neither type
of value set is able to account for valuation differences
rooted in responder heterogeneity. Different patients
often value the same health state differently. In case of
systematic variation, a variety of utilities might thus be
needed for the same health state.
In a first step, effects of patient heterogeneity on
health perception can be analyzed for the problem-free
health state that is reported most frequently in general
population studies. For example, a comparison of
EQ-5D-3L population studies in Germany, Spain, the
UK, and the US found the share of this state to vary
between 47 and 67% [12]. Even when using the more
differentiated EQ-5D-5L, this health state represented
a share of 61% in the general German population [13].
Despite selecting not having any problems, many older
participants report significantly lower VAS scores than
younger people who are problem-free [13]. While the
age-based decline in health state and VAS score has
been observed elsewhere [13–15], the decline in VAS
scores among people reporting being problem-free
should be investigated, as it reflects discrepancy be-
tween values assigned from a value set and an individ-
ual’s health perception (VAS score). Problems with the
EQ-5D deviating from the best health state are known
[16]. Taking the example of Germany, this study inves-
tigates the relationship between the problem-free
health state of the EQ-5D-5L and self-reported VAS
scores. Sociodemographic parameters and other pa-
rameters such as disease affliction are evaluated to as-
sess their influence on variation in health perception.
Methods
Study population
Three cross-sectional surveys (2012, 2013, 2014) were
used in this study. These surveys were conducted annu-
ally. To ensure that participants are representative of the
general German population, a random route procedure
was used to select around 2000 participants per year.
The random route procedure and additional survey con-
tent are described in more detail elsewhere [13].
Survey content
The yearly surveys include questions about healthcare
habits as well as healthcare status of participants and have
incorporated the EQ-5D-5L since 2012. The survey in-
cludes questions regarding sociodemographic data, disease
affliction, healthcare utilization, and HRQoL. Evaluated
parameters, among others, include age, sex, height,
weight, education (low education: primary school;
medium education: secondary school certificate; high edu-
cation: general qualification for university entrance or ad-
vanced technical college entrance qualification), job status
(self-employed, public servant, employee, worker, un-
employed), and the presence of disease. Disease affliction
and other parameters are based on self-report by partici-
pants and were not assessed by clinical means. Partici-
pants were asked to name diseases they had suffered from
during the last 3 months before the survey. Cold, flu, mi-
graine and tooth problems were considered as acute oc-
currence, the other diseases were considered as chronic.
HRQoL
The EQ-5D-5L is a generic tool that can be used among
different fields of indication. It is well accepted by
healthcare authorities such as the National Institute for
Health and Care Excellence (NICE) and was used in
each of the three surveys. For the purpose of this study,
the health state 11111 (no problem in any dimension) is
referred to as being problem-free. In addition to the five
dimensions, the respondents were also asked to rate
their current health on the VAS.
Data analysis
Datasets from 2012, 2013, and 2014 were merged and
tidied. Participants with N/As for the EQ-5D-5L descrip-
tive system and/or VAS result were removed. Body mass
index (BMI) was grouped based on WHO classification
recommendations [17]. Only diseases that were stated
by more than five survey takers per gender were in-
cluded in the analysis to improve the clarity of the paper
as well as the clinical transferability of the results irre-
spective of gender. While linear models assume homo-
scedasticity of error terms, this assumption is often
violated by HRQoL data, as a majority of participants
often report very good health states. The Breusch–Pagan
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test was highly significant for our linear model, indicat-
ing that variance of regression errors is heteroscedastic.
To receive heteroscedasticity-consistent standard errors,
we calculated sandwich estimators [18]. Robust regres-
sion is based on less restrictive assumptions and repre-
sents an alternative to least squares regression when
error terms are heteroscedastic [19]. All analyses are
based on the software environment R [20], version 3.4.0.
Figures were created using the package ggplot2 [21].
Results
The total sample included 6074 observations, of which
3739 (61.5%) participants reported to be problem-free
(11111). Table 1 shows the sample characteristics. The
mean age was 41.1 years and the mean VAS score was
around 91.9. The mean VAS score for problem-free
participants who reported not having any disease
(not shown here) is 93.51 (n = 2493). Less than a quarter
had high education (general qualification for university
entrance or advanced technical college entrance qualifica-
tion). The majority were living together with other house-
hold members. Females suffered from more chronic
diseases. More than three-quarters of participants were ei-
ther employees or workers. Overall, 12.2% did not answer
the question about employment. Of those participants
who stated their height and body weight, 56.8% had a nor-
mal BMI and 41.1% were considered to be overweight/
obese. There were 12 participants with diseases of the eye,
six participants with diseases of the ear, and only four par-
ticipants with depression (not shown here). The most
common chronic diseases were musculoskeletal diseases
and hypertension. Variation of observed variables among
the three survey years was generally low [13, 22].
The share of participants who are affected by specific
diseases and report no problem in the descriptive system
differs greatly among diseases (Fig. 1). While around
60% with bladder disease, dental disease, or allergy re-
port being problem-free, only around 20% do so when
they are affected by diabetes, musculoskeletal disease, or
heart disease.
Overall, median VAS scores decline and interquartile
ranges increase by age group (Fig. 2). Median VAS scores
are quite similar for age groups 14–19 and 20–29 years
(around 98), 30–39 and 40–49 years (around 95), as well
as 50–59 and 60–69 years (around 90). Outliers are
present in every age group. The sample size of age group
80+ years is small.
Table 2 shows the results of the multiple linear regres-
sion model with respective sandwich estimators. Female
gender and older age are significantly associated with
lower VAS scores. Overweight and obesity classes I + III
are associated with lower VAS scores, while being
underweight has no significant influence. Employment
Table 1 Sample characteristics
Characteristic Male Female Total
Population 1911 (51) 1828 (49) 3739 (100)
Mean age (years) 41.3 (±15.5) 40.8 (±15.4) 41.1 (±15.5)
Mean VAS 92.4 (±9.0) 91.3 (±9.4) 91.9 (±9.2)
Education
Low 611 (17.3) 533 (15.1) 1144 (32.4)
Medium 712 (20.2) 844 (24.0) 1556 (44.2)
High 470 (13.3) 354 (10.0) 824 (23.3)
Living with partner
No 874 (23.4) 779 (20.8) 1653 (44.2)
Yes 1037 (27.7) 1049 (28.1) 2086 (55.8)
Household size
> 1 person 1316 (35.2) 1405 (37.6) 2721 (72.8)
1 person 595 (15.9) 423 (11.3) 1018 (27.2)
Employment
Self-employed 193 (5.2) 97 (2.6) 290 (7.8)
Public servant 79 (2.1) 41 (1.1) 120 (3.2)
Employee 778 (20.8) 1277 (34.1) 2055 (54.9)
Worker 622 (16.6) 178 (4.8) 800 (21.4)
Unemployed 4 (0.1) 13 (0.3) 17 (0.4)
Not available 235 (6.3) 222 (5.9) 457 (12.2)
BMI
Mean BMI (SD) 25.23 (±2.9) 23.79 (±3.9) 24.54 (±3.6)
Underweight (< 18.5) 5 (0.1) 68 (2.0) 73 (2.2)
Normal weight (18.5–24.9) 891 (26.5) 1018 (30.3) 1909 (56.8)
Overweight (25–29.9) 786 (23.4) 406 (12.1) 1192 (35.5)
Obesity class I (30–34.9) 73 (2.2) 80 (2.4) 153 (4.6)
Obesity class II (35–39.9) 12 (3.6) 13 (0.4) 25 (0.7)
Obesity class III (≥40) 3 (0.1) 6 (0.2) 9 (0.3)
Disease
Allergy 10 (0.3) 30 (0.8) 40 (1.1)
Asthma 8 (0.2) 15 (0.4) 23 (0.6)
Bladder 2 (0.1) 23 (0.6) 25 (0.7)
Colda 135 (3.6) 176 (4.7) 311 (8.3)
Diabetes 19 (0.5) 25 (0.7) 44 (1.2)
Flua 48 (1.3) 50 (1.3) 98 (2.6)
Gut 46 (1.2) 56 (1.5) 102 (2.7)
Heart 12 (0.3) 11 (0.3) 23 (0.6)
Hypertension 47 (1.3) 69 (1.8) 116 (3.1)
Migrainea 79 (2.1) 157 (4.2) 236 (6.3)
Musculoskeletal 73 (1.9) 63 (1.7) 136 (3.6)
Skin 12 (0.3) 19 (0.5) 31 (0.8)
Tootha 28 (0.7) 35 (0.9) 63 (1.6)
Thyroid 5 (0.1) 38 (1.0) 43 (1.1)
Percentage or SD in brackets; BMI body mass index; low education: primary
school; medium education: secondary school certificate; high education:
general qualification for university entrance or advanced technical college
entrance qualification
aconsidered as acute diseases, other diseases considered as chronic
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status is borderline but currently not significant.
Medium and high education are associated with higher
VAS scores. Obesity class III and diabetes have the
strongest negative significant influence and lower VAS
scores by 9.0 and 8.4 points respectively.
Diabetes has the strongest significant negative effect on
VAS results. Figure 3 illustrates VAS means of diabetics
and non-diabetics, who reported being problem-free,
stratified by age group. While there are no diabetics in age
group 14–19 years, the difference in VAS means increases
Fig. 1 Percentage of participants with specific diseases reporting no problems, bar chart. Note: Percentage of people who are affected by diseases but
report no problems, e.g., 59.7% of survey participants who reported having an allergy also reported having no problems in the five dimensions of the
EQ-5D-5L (= 11111). Hyper.: Hypertension; Migr.: Migraine; Musc.: Musculoskeletal disease
Fig. 2 Boxplots of VAS results stratified by age group
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from around 10 points in age group 20–29 years to
around 20 points for age group 30–59 years, before it
narrows again.
Discussion
We clearly show that VAS scores among people who re-
port to be problem-free suffer from systematic variation.
While a majority of young people report VAS scores of
100, mainly older people and participants with certain
diseases do not. Older adults with low education, obes-
ity, and chronic diseases such as diabetes or cardiac dis-
ease seem to be especially prone to reporting low VAS
scores despite stating no problems in the EQ-5D-5L de-
scriptive system.
Additional factors influencing VAS responders
One possible explanation for this discrepancy is the
weakness of the five dimensions in reflecting all limita-
tions of associated diseases. Respective evidence is avail-
able for macular degeneration, hearing disorders, and
psychotic disease [23–28]. However, the number of
people with self-reported visual or hearing disorders or
depression was very low in our sample. One basic short-
coming of the EQ-5D-3L compared with the 15D instru-
ment is its problem in deviating from 11111, especially
for alcohol use disorders, migraine, psoriasis, and dis-
turbing allergy [16]. Because we use the 5L version and
have differing disease focus, the impact of this problem
on our observations can hardly be assessed. 179 respon-
dents out of a sample of 436 participants of the UK gen-
eral population stated aspects that were important but
missing from the five dimensions of the EQ-5D [28].
Sensory deprivation (50 responses) and mental health
(72 responses) were mentioned the most. Overall, simple
having or not having a disease, irrespective of symptoms,
may represent an important aspect of health that ex-
plains lower VAS results in some people and should
therefore be taken into consideration. 15 respondents
also complained that a reference for communication was
missing, 13 missed a dimension for lifestyle and fitness,
10 missed non-health outcomes (work, financial stabil-
ity), 15 missed a dimension regarding relationships,
loneliness and sociability, 6 missed spirituality and 4
tiredness. These aspects may influence VAS responses
but based on current data of this study it is not possible
to decipher their degree of influence. Disease-specific
sensitivity problems of the EQ-5D-3L and 5L are cur-
rently addressed by implementing so-called bolt-on
items. They are currently available for psoriasis,
disorders of the eye and ear, or sleeping disorders [25,
29–32]. A bolt-on item for respiratory disease is cur-
rently under development [33]. Bolt-on items take the
same form as other EQ-5D questions but focus on add-
itional disease dimensions, where the performance of
the EQ-5D is currently suboptimal. The introduction of
the EQ-5D-5L version may have improved performance
to some degree, on account of increased sensitivity and
fewer ceiling effects, especially in older people [34, 35].
Table 2 Parameter estimates, robust regression, VAS as dependent
variable
Estimate Std. error Pr(>|t|) Significance
(Intercept) 98.3150 2.2046 0.0000 ***
Sex −0.8091 0.2861 0.0047 **
Age −0.2063 0.0115 0.0000 ***
Education
Low Reference
Medium 0.7643 0.3260 0.0191 *
High 0.9874 0.3767 0.0088 **
Employment status
Unemployed Reference
Employed 4.0233 2.1912 0.0664 .
No answer 3.8399 2.1863 0.0791 .
Public servant 4.1347 2.3132 0.0740 .
Self-employed 3.9145 2.2546 0.0826 .
Worker 3.9608 2.2051 0.0725 .
BMI
Normal weight Reference
Underweight 0.7083 0.6040 0.2410
Overweight −1.6191 0.3009 0.0000 ***
Obesity class I −3.1870 0.8692 0.0002 ***
Obesity class II −3.1904 1.6789 0.0575 .
Obesity class III −9.0364 3.0929 0.0035 **
Disease affliction Binary
Allergy 0.1723 1.9057 0.9280
Asthma −3.6867 2.9752 0.2154
Cold 1.0383 1.2530 0.4073
Diabetes −8.4187 2.2352 0.0002 ***
Flu 1.4430 1.3633 0.2899
Heart disease −6.1609 2.8770 0.0323 *
Hypertension −2.6707 1.5183 0.0787 .
Gut 0.9271 1.5420 0.5477
Migraine −0.4713 1.2814 0.7131
Musculoskeletal disease −3.3929 1.5141 0.0251 *
Periodontal disease 0.5671 1.4143 0.6885
Skin disease −1.2974 2.5502 0.6110
Thyroid disease −1.9188 2.4029 0.4246
One disease −3.2772 1.2155 0.0070 **
Two diseases −3.8294 2.1846 0.0797 .
Three diseases −4.8167 3.5382 0.1735
Four diseases −8.2427 5.5741 0.1393
Significance levels:. p < 0.1, * p < 0.05, ** p < 0.01, *** p < 0.001
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Nevertheless, the five EQ-5D dimensions remain the
same, and health problems not reflected in these dimen-
sions are likely missed in the new version as well.
Accordingly, the 50th percentile of VAS scores in our
sample of problem-free participants is 90 for age group
50–69 years and 85 for age group 70+ years.
Shah et al. [36] also evaluated the influence of wording
used for being problem-free, on valuation outcomes in
TTO studies. Over 40% of Shah et al.’s respondents stated
that important aspects of health were not covered by the
five EQ-5D dimensions. Moreover, the authors stated:
“224 respondents (50.6%) self-reported as being in health
state 11111. Of these 224 respondents, 187 (83.5%)
self-reported an EQ-VAS score of less than 100 (…) The
mean (median) EQ-VAS score for respondents
self-reporting as being in 11111 was 89.1 (90).” This con-
firms our findings; the VAS is an important supplement to
the descriptive system and should not be disregarded as it
contains information that is not reflected by currently
assigned values, which are only based upon the descriptive
part of the EQ-5D, especially the value for 11111.
Current value sets for the EQ-5D-5L
An overview of available official value sets for the
EQ-5D-5L and their respective values for the
problem-free health state may help to assess the extent of
this issue. Eight value sets for eight different countries are
currently (August 2017) listed on the EuroQol site [7]. At
least six of these value sets (China, England, Indonesia,
Korea, Netherlands, Uruguay) propose 1 as the value for
11111 [37–42]. Interestingly, Luo et al. [41] point toward
another issue with some value sets: “Although most previ-
ous studies of this kind chose to adjust only the value for
11111 (to 1), we elected to adjust all the values to preserve
the relative utility of all the health states.” Therefore, to
fulfill the criteria of the QALY concept, some authors
manually set the value for 11111 to 1, while their actual
models proposed lower utilities for the best health state.
Remaining values were not adjusted in most of these stud-
ies, and it is unclear which approach should be preferred.
Xie et al. [43], in their value set for Canada, extrapolated
their preferred model and calculated 0.949 to be the value
for being problem-free. They state that optimal health
may go beyond not having any problems in the five di-
mensions of the EQ-5D-5L. Our findings support this
conclusion and point out that even more differentiation
might be necessary. Before choosing a value set, modelers
and decision makers should be aware of their perspective
and respective implications. From a population perspec-
tive, assigning utilities of 1 to all people in the
problem-free health state may be correct but from a pa-
tient perspective it frequently is not.
Impact
The focus on patient outcomes is increasing in
Germany [44] and around the world [45]. For ex-
ample, the National Health Service requires providers
to collect patient-reported outcome measures
(PROMs) for several elective procedures and, overall,
PROMs are becoming more and more important for
healthcare providers and decision makers [46]. How-
ever, the observed systematic variations in individual
health perception are not captured by value sets
based on health state descriptions as, for one health
state, these will always attribute one value (both
utility-based value sets and experience-based value
Fig. 3 VAS mean by age groups, non-diabetics vs. diabetics, problem-free only. Note: There were no diabetics in age group 14–19 years
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sets). As shown, systematic deviations in valuations
can reach ranges of clinically minimally important dif-
ferences [47, 48] and thus affect assessment in a sub-
stantial way. Furthermore, quality of life loss was
found to vary by age for respondents reporting dia-
betes, reaching especially high levels in those between
30 and 60 years of age. If the systematic deviations in
valuations are considered relevant both in size and
with regard to the research question, it is necessary
to test whether or not an EQ-5D value set is a valid
measure in a target group of responders; this applies
especially if older age, higher BMI, and specific dis-
eases prevail. Disregarding this systematic variation in
valuation may lead to overestimation as well as
underestimation of the health gains that are achiev-
able by intervention. Moreover, the current health
status of patients may be misrepresented when VAS
scores are disregarded.
Strength and limitations
One strength of this study is the random route proced-
ure that was used to select participants. This sophisti-
cated method improves the representativeness of the
study population and minimizes selection bias.
Moreover, to our knowledge, this is the first study to
evaluate systematic variation between the assigned value
for 11111 and actually perceived health in Germany.
One limitation of this study is that certain biases may
have influenced results. For example, respondents are
often more inclined to report non-extreme answers on
rating scales (central tendency bias). This is especially
important for the VAS, as it ranges from 0 to 100 and
does not include descriptions for predefined sections of
the scale. However, if the central tendency bias is
present, it should exist throughout all age groups. This
is not the case in our study, with young people mostly
reporting VAS scores of 100 and older people tending to
report lower scores. Unless the central tendency bias in-
creases with older age, its presence cannot be confirmed
in our data. Evidence exists, that increased cognitive
loads increase the central tendency bias [49] but we are
unaware of evidence evaluating cognitive loads based on
age. Another limitation of this study is the lack of clear
definitions for certain diseases, e.g., the term skin disease
subsumed a wide variety of skin diseases that differ in
severity and impact on patient HRQoL. Moreover, sig-
nificant predictors that go beyond our evaluated inde-
pendent variables were missed, and thus could not be
used to explain the variation. Other aspects of
well-being like aesthetics, cognitive capabilities, relation-
ships or communication may influence VAS responses.
While this issue certainly deserves more research, this
was not possible within the scope and data of this study.
Finally, the variation has “only” been shown for the most
frequent health state—which is highly relevant in general
population surveys—but it remains unclear to what ex-
tent other health states are affected by the phenomenon.
Furthermore, the question of why individual health per-
ception differs between a descriptive system and VAS is
not the focus of this paper. More research may be
needed in this regard. Our research goal was to evaluate
the existence of systematic variation among health per-
ceptions and what the respective predictors look like in
our sample.
Conclusion
In an era in which individual health outcomes have be-
come the new focus of healthcare, adequate valuation
for health states including different population groups
becomes necessary. Focusing on the large share of the
general population not reporting any problem in the
EQ-5D descriptive system, a single value for all has been
found not to adequately reflect actual health valuation
for several subgroups, especially for older people with
high BMI and those affected by specific diseases. If such
heterogeneity is present and impacts study results, indi-
vidual health perception should be considered, and VAS
results should not be disregarded.
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